FDA to weigh peptide access
The U.S. Food and Drug Administration said it will convene outside advisers in July to consider whether licensed compounding pharmacies should be allowed broader access to manufacture several popular peptides. The meeting is intended to inform policy on manufacturing access for these therapeutics. (reuters.com)
The Food and Drug Administration will ask outside advisers in July whether pharmacies should be allowed to compound seven restricted peptides again. (fda.gov) The meeting is set for July 23 and 24 at the agency’s White Oak campus in Silver Spring, Maryland, with a webcast and a public comment docket that closes July 22. The committee’s advice is nonbinding, but the Food and Drug Administration says these panels help shape agency decisions. (federalregister.gov, fda.gov) A peptide is a short chain of amino acids, the chemical building blocks of proteins. The July agenda covers BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax, and Epitalon, with uses the agency reviewed including ulcerative colitis, wound healing, inflammatory conditions, obesity, osteoporosis, sleep, and memory. (fda.gov) The policy fight centers on the Section 503A bulks list, which governs which raw drug ingredients traditional compounding pharmacies may use. The Food and Drug Administration says Category 2 substances may present significant safety risks and are generally not eligible for routine compounding. (fda.gov) That matters because many of these products are not approved drugs sold by manufacturers, but custom-made preparations mixed by pharmacies for individual patients. The Food and Drug Administration said on April 1 that compounders still must avoid making products that are essentially copies of commercially available drugs unless narrow exceptions apply. (fda.gov) The agency tightened access in 2023, when it moved 19 peptides into Category 2 after advisers and staff cited limited human safety data, peptide-related impurities, and immunogenicity risk, meaning the body could react against the drug. Reuters and STAT reported the July meeting will revisit seven of those substances, with another meeting planned before the end of February 2027 for five more. (fda.gov, statnews.com, kfgo.com) The push to reopen access has come from Health and Human Services Secretary Robert F. Kennedy Jr., who told podcaster Joe Rogan in February that he wanted peptides to be easier to get. The Associated Press reported the products have also been promoted by wellness influencers and sellers who pitch them for muscle gain, injury recovery, and anti-aging. (abcnews.com, statnews.com) Critics say the science has not changed enough to justify a reversal. The Center for Science in the Public Interest said on April 15 that the planned review could expand access to injectable compounds used for unproven benefits, while ProPublica reported former Food and Drug Administration officials say the 2023 safety concerns were backed by documented evidence and that little new science has emerged since then. (cspi.org, propublica.org) Supporters of broader access argue the restrictions pushed patients toward a gray market of online sellers and research-grade products. The Alliance for Pharmacy Compounding said in a public statement after the 2023 crackdown that prescribers and compounders needed clearer rules on peptide products under federal law and Food and Drug Administration guidance. (a4pc.org) The next decision point is now on the calendar. By late July, the Food and Drug Administration will have a public record, outside recommendations, and a clearer test of whether it plans to keep the 2023 peptide limits in place or start unwinding them. (federalregister.gov, fda.gov)
